CONCORDBIO - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | CONCORDBIO | Market Cap | 11,947 Cr. | Current Price | 1,142 ₹ | High / Low | 2,150 ₹ |
| Stock P/E | 37.6 | Book Value | 174 ₹ | Dividend Yield | 0.94 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,114 ₹ | DMA 200 | 1,351 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.36 % | PAT Qtr | 70.2 Cr. | PAT Prev Qtr | 62.9 Cr. |
| RSI | 61.9 | MACD | -1.21 | Volume | 3,20,331 | Avg Vol 1Wk | 5,43,102 |
| Low price | 987 ₹ | High price | 2,150 ₹ | PEG Ratio | 1.40 | Debt to equity | 0.00 |
| 52w Index | 13.3 % | Qtr Profit Var | -5.20 % | EPS | 30.1 ₹ | Industry PE | 30.1 |
📊 CONCORDBIO shows strong fundamentals with ROE (21.4%) and ROCE (28.4%), supported by zero debt-to-equity, ensuring financial stability. EPS of ₹30.1 reflects earnings strength, while quarterly PAT growth (70.2 Cr vs 62.9 Cr) highlights operational improvement. However, trading below the 200 DMA (1,351 ₹) and negative MACD (-1.21) indicate weak momentum. Valuation remains stretched with P/E (37.6) above industry average (30.1), though PEG ratio (1.40) suggests moderate growth-adjusted value.
🎯 Entry Zone: 1,130 ₹ – 1,145 ₹ (support near 50 DMA)
📌 Long-Term Holding: Suitable for accumulation with cautious exposure. Strong fundamentals support stability, but earnings volatility and weak technical momentum warrant disciplined entry and monitoring.
Positive
- Zero debt ensures financial resilience.
- Strong ROCE and ROE highlight operational efficiency.
- EPS of ₹30.1 supports earnings strength.
- FII holdings increased (+0.21%), showing foreign investor confidence.
Limitation
- Trading below 200 DMA indicates medium-term weakness.
- Negative MACD (-1.21) reflects weak momentum.
- Quarterly profit variation (-5.20%) shows earnings volatility.
- DII holdings declined (-0.36%), reflecting domestic investor caution.
Company Negative News
- No major negative news reported; earnings volatility remains a concern.
Company Positive News
- Quarterly PAT growth (70.2 Cr vs 62.9 Cr) shows operational improvement.
- Strong fundamentals with zero debt and efficiency ratios.
Industry
- Industry P/E at 30.1 suggests CONCORDBIO is trading at a premium (P/E 37.6).
- Biopharma sector remains volatile but supported by long-term demand.
Conclusion
⚡ CONCORDBIO is fundamentally stable with strong efficiency and zero debt. Entry around 1,130–1,145 ₹ offers limited upside, with exit targets near 1,170–1,190 ₹. Long-term holding is justified by strong fundamentals, but medium-term weakness and earnings volatility warrant cautious accumulation.
This gives you a balanced fundamental view of CONCORDBIO. If you’d like, I can extend this into a sector benchmarking overlay comparing CONCORDBIO against peers like BIOCON or DIVIS LABS to highlight relative valuation and efficiency positioning. Would you like me to prepare that next?